Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Carbohydrate Counting in the Real World: Mealtime Insulin Dosing Behaviors and Smartphone App Use in Adults with Type 1 Diabetes

Everett EM, Shaw E, Escobar B, Cheng D, Tiu R, Lopez R, Menjivar Cruz J, Rivas Deras A, Polan D, Wisk LE, Moin T. Carbohydrate[...]

Exposure to per-and polyfluoroalkyl substances and early-onset cancers

van Gerwen M, Monaghan M, Boni A, Florentino Puello M, Petrick LM, Leung AM. Exposure to per-and polyfluoroalkyl substances and early-onset cancers. Carcinogenesis. 2026 Jul[...]

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic[...]